NEW YORK (GenomeWeb News) – Compugen this week said that it has inked a deal to license to an unnamed diagnostic firm the biomarker candidate CGEN-226 for early detection of preeclampsia. Compugen used its in silico platform to identify the marker, which is a soluble splice variant of the vascular endothelial growth factor. (This brief has been corrected to state that Compugen licensed the biomarker to the unnamed partner rather than from the partner.)

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.